The global hypopituitarism diagnostics market is expected to garner a market value of US$ 250 Million in 2023 and is expected to accumulate a market value of US$ 447.41 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Hypopituitarism Diagnostics registered a CAGR of 4% in the historical period 2017 to 2022.
Hypopituitarism happens when your pituitary gland is not active enough, resulting in the gland not making enough hormones. The major factors attributing to the growth of the market are pituitary tumors, Infections or inflammatory diseases, and the increasing prevalence of hormonal problems. Furthermore, the increasing number of people suffering from autoimmune diseases and genetic diseases are also the major factors that help in driving the growth of the market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 250 Million |
| Anticipated Forecast Value (2033) | US$ 447.41 Million |
| Projected Growth Rate (2023 to 2033) | 6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Hypopituitarism Diagnostics reflected a value of 4% during the historical period, 2018 to 2022. Urban lifestyles and degrading food habits are expected to increase the demand for hypopituitarism diagnostics and treatment facilities.
Due to the hectic life patterns of the citizens working in cities, there has been an observed increase in stress and sleeplessness. These challenges are emerging as the main factor for the deteriorating health in the urban population by disrupting the hormonal balance in the human body. Medication growth hormones are the appropriate short-term remedies for such situations that are getting more and more popular among youngsters and old age people equally around the world.
In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of the Hypopituitarism Diagnostics Market is fuelling the market growth. Thus, the market for hypopituitarism diagnostics is expected to register a CAGR of 6% in the forecast period 2023 to 2033.
Strong Relation Between Hypopituitarism and Growth Hormone Deficiency to push the market growth
The human growth hormone helps to stimulate regeneration, reproduction, and growth. Rising use of growth hormones and awareness about growth hormones, which help in the management of growth hormone deficiency disorders, are boosting the market growth. The strong connection between growth hormone deficiency and Hypopituitarism Diagnostics disease is one of the biggest drivers of the market.
According to a research article by Mohamed Hamdy Elkarow et al., published in the Frontiers in Endocrinology Journal in November 2020, patients with decreased growth hormone secretion constitute a risk factor for COVID-19 severity, which requires attention toward preventive measures in susceptible individuals. Though growth hormone deficiency among humans is a rare condition with a chance of 0.001% on a global scale, it creates an immense opportunity for business ventures in the market.
Furthermore, most companies are investing in Research and Development
to develop a growth hormone that has fewer side effects and will be a long-acting hormonal therapy. In addition, the rapid development of new novel recombinant human growth hormones is expected to drive the hypopituitarism market over the forecast period. Considering these factors, the market is projected to show considerable growth through 2033.
Increased Prevalence of Hypopituitarism in Pregnant Women to Bolster the Treatments’ Demand
According to an analysis conducted by National Center for Biotechnology Information, hypopituitarism is associated with an increased risk of pregnancy complications, such as abortion, anemia, pregnancy-induced hypertension, placental abruption, premature birth, and postpartum hemorrhage.
Women with hypopituitarism often need assisted reproductive treatment, with pregnancy rates ranging from 47% to 100%. In patients achieving pregnancy, the live birth rate ranged from 61% to 100%. While glucocorticoids, levothyroxine, and desmopressin are safely prescribed during pregnancy, growth hormone treatment regimens vary significantly between countries, and several publications support a positive effect in women seeking fertility.
Considering the above-mentioned insights, replacement of deficient hormones remains the main treatment modality for hypopituitarism, and the order of treatment is a glucocorticoid, thyroid hormone, sex hormone, and growth hormone. In general, thyroid hormone replacement should be initiated two weeks after glucocorticoid replacement, and it is advisable, to begin with, a low dosage to prevent an Addisonian crisis.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Hypopituitarism Diagnostics, less awareness of Hypopituitarism Diagnostics disease, and insubstantial treatment options are hampering the market growth.
Improvement in healthcare spending propelling the growth of Hypopituitarism Diagnostics in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Hypopituitarism Diagnostics Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the treatment market worldwide.
Technological Advancements Shaping Landscape for Hypopituitarism Diagnostics in North America
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. As per the American Academy of Pediatrics, growth hormone deficiency is a rare condition that affects less than one in 3,000 to one in 10,000 children in the USA.
In addition to this, increasing awareness about growth hormone deficiencies and treatment is expected to boost market growth. Every year, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP) celebrates Children’s Growth Awareness Day to spread awareness about the early diagnosis and treatment of growth hormone disorders.
Furthermore, due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, efficient treatments are being introduced.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hospitals to take the lead and drive market growth
The application segment has been divided into hospitals, home care, and clinics. According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the hypopituitarism diagnostics facilitates the growth of this segment.
Key start-up players in the Hypopituitarism Diagnostics Market are-
Key players in the Hypopituitarism Diagnostics Market are Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories Inc., Danaher Corporation, Siemens AG, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, and Thermo Fisher Scientific.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 250 Million |
| Market Value in 2033 | US$ 447.41 Million |
| Growth Rate | CAGR of 6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The growing prevalence of hypopituitarism driving the growth in the China region.
The availability of reimbursements for diagnostic tests is driving the growth in Germany.
The booming healthcare sector has necessitated hypopituitarism diagnostics services.
The United States held 28% of the global market share in 2022.
High cost and insubstantial treatment options.
1. Executive Summary | Hypopituitarism Diagnostics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033
5.3.1. Hormone Stimulation Tests
5.3.2. MRI or CT Scan
5.3.3. Visual Field Check
5.3.4. Insulin Tolerance Test
5.4. Y-o-Y Growth Trend Analysis By Test Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Test Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.3.3. Academic Research Institutes
6.3.4. Others
6.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa(MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Test Type
8.2.3. By End Users
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Test Type
8.3.3. By End Users
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Test Type
9.2.3. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Test Type
9.3.3. By End Users
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Test Type
10.2.3. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Test Type
10.3.3. By End Users
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Test Type
11.2.3. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Test Type
11.3.3. By End Users
11.4. Key Takeaways
12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of Middle East and Africa(MEA)
12.2.2. By Test Type
12.2.3. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Test Type
12.3.3. By End Users
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. USA
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Test Type
13.1.2.2. By End Users
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Test Type
13.2.2.2. By End Users
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Test Type
13.3.2.2. By End Users
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Test Type
13.4.2.2. By End Users
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Test Type
13.5.2.2. By End Users
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Test Type
13.6.2.2. By End Users
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Test Type
13.7.2.2. By End Users
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Test Type
13.8.2.2. By End Users
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Test Type
13.9.2.2. By End Users
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Test Type
13.10.2.2. By End Users
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Test Type
13.11.2.2. By End Users
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Test Type
13.12.2.2. By End Users
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Test Type
13.13.2.2. By End Users
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Test Type
13.14.2.2. By End Users
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Test Type
13.15.2.2. By End Users
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Test Type
13.16.2.2. By End Users
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Test Type
13.17.2.2. By End Users
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Test Type
13.18.2.2. By End Users
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Test Type
13.19.2.2. By End Users
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Test Type
13.20.2.2. By End Users
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Test Type
14.3.3. By End Users
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Abbott Laboratories
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Becton, Dickinson and Company
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. BioMerieux
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Bio-Rad Laboratories Inc.
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Danaher Corporation
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Siemens AG
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Hologic Inc.
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Qiagen NV
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. F. Hoffmann-La Roche AG
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Thermo Fisher Scientific
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Healthcare
January 2023
REP-GB-16359
297 pages
Explore Healthcare Insights
View Reports
Hypopituitarism Diagnostics Market
